结直肠癌中的阴性预测生物标志物：稳步推进。 - Suppr

Suppr

超能文献

Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead.

作者信息

Sundar Raghav, Tan Iain Bee Huat, Chee Cheng E

机构信息

National University Health System, Singapore.

Duke-National University of Singapore Medical School, Singapore.

出版信息

J Clin Oncol. 2019 Nov 20;37(33):3066-3068. doi: 10.1200/JCO.19.01977. Epub 2019 Sep 24.

DOI:10.1200/JCO.19.01977

PMID:31550189

Abstract

摘要

相似文献

Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead.结直肠癌中的阴性预测生物标志物：稳步推进。

J Clin Oncol. 2019 Nov 20;37(33):3066-3068. doi: 10.1200/JCO.19.01977. Epub 2019 Sep 24.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.野生型BRAF是转移性结直肠癌对帕尼单抗或西妥昔单抗产生反应所必需的。

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.帕尼单抗联合 FOLFOX4 治疗与结直肠癌的 RAS 突变。

N Engl J Med. 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275.

Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.在经化疗治疗后进展的野生型 KRAS 转移性结直肠癌的帕尼单抗联合最佳支持治疗的随机 3 期研究中的最终生存分析和 RAS/BRAF 状态。

Clin Colorectal Cancer. 2018 Sep;17(3):206-214. doi: 10.1016/j.clcc.2018.03.008. Epub 2018 Mar 21.

Panitumumab in the treatment of colon cancer: A biomarker dilemma.帕尼单抗治疗结肠癌：生物标志物困境

Drugs Today (Barc). 2014 Oct;50(10):679-90. doi: 10.1358/dot.2014.50.10.2221787.

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.转移性结直肠癌抗表皮生长因子受体治疗中的预后和预测生物标志物

World J Gastroenterol. 2016 Aug 14;22(30):6944-54. doi: 10.3748/wjg.v22.i30.6944.

BRAF testing in advanced colorectal cancer: is it ready for prime time?晚期结直肠癌中的BRAF检测：它是否已准备好进入黄金时代？

Clin Adv Hematol Oncol. 2010 Jun;8(6):437-44.

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?结直肠癌的预后与预测性分子生物标志物：抗 EGFR 治疗是否需要 KRAS 和 BRAF 野生型状态？

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9.

Prognostic and predictive biomarkers in nonmetastatic colorectal cancers.非转移性结直肠癌中的预后和预测生物标志物

Future Oncol. 2018 Sep;14(21):2097-2102. doi: 10.2217/fon-2017-0708. Epub 2018 Aug 13.

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.结直肠癌中对西妥昔单抗和帕尼单抗耐药的分子机制。

J Clin Oncol. 2010 Mar 1;28(7):1254-61. doi: 10.1200/JCO.2009.24.6116. Epub 2010 Jan 25.

引用本文的文献

Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review.转移性结直肠癌一线抗表皮生长因子受体治疗中的阴性超选择：一项叙述性综述

Int J Mol Sci. 2025 Feb 28;26(5):2216. doi: 10.3390/ijms26052216.

An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study.基于外泌体的液体活检预测转移性结直肠癌患者对西妥昔单抗和帕尼单抗的反应深度及生存结果：EXONERATE研究

Clin Cancer Res. 2025 Mar 17;31(6):1002-1015. doi: 10.1158/1078-0432.CCR-24-1934.

Crosstalk Between Cancer-associated Fibroblasts and Myeloid Cells Shapes the Heterogeneous Microenvironment of Gastric Cancer.癌症相关成纤维细胞与髓样细胞之间的串扰塑造了胃癌的异质性微环境。

Curr Genomics. 2024;25(5):390-411. doi: 10.2174/0113892029300608240531111743. Epub 2024 Jun 11.

Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.在氟尿嘧啶、伊立替康和奥沙利铂耐药 RAS 和 BRAF 野生型转移性结直肠癌患者中，抗 EGFR 单克隆抗体 SCT200 的疗效、安全性和基因组分析：一项Ⅱ期研究。

EBioMedicine. 2024 Feb;100:104966. doi: 10.1016/j.ebiom.2024.104966. Epub 2024 Jan 13.

Tri©DB: an integrated platform of knowledgebase and reporting system for cancer precision medicine.Tri©DB：癌症精准医学知识库和报告系统的集成平台。

J Transl Med. 2023 Dec 6;21(1):885. doi: 10.1186/s12967-023-04773-5.

Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies.靶向胃肠道原发性恶性肿瘤中的间变性淋巴瘤激酶

JCO Precis Oncol. 2022 Jul;6:e2200208. doi: 10.1200/PO.22.00208.

KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves.KMSubtraction：利用已发表的 Kaplan-Meier 生存曲线重建未报告亚组生存数据。

BMC Med Res Methodol. 2022 Apr 3;22(1):93. doi: 10.1186/s12874-022-01567-z.

Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.胃肠道肿瘤免疫编辑和免疫检查点抑制耐药中的表观遗传启动子改变。

Gut. 2022 Jul;71(7):1277-1288. doi: 10.1136/gutjnl-2021-324420. Epub 2021 Aug 25.

Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination.胃癌患者原发灶和局部转移灶配对的空间分析揭示了肿瘤转移的原则。

Gut. 2021 Oct;70(10):1823-1832. doi: 10.1136/gutjnl-2020-320805. Epub 2020 Nov 23.

Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review.局部晚期结肠癌的新辅助治疗：一项荟萃分析与系统评价

J Gastrointest Oncol. 2020 Oct;11(5):847-857. doi: 10.21037/jgo-20-220.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验